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ORIGINAL ARTICLE
Sympathetic activation plays an important role in
the compensatory response to and the progress of
heart failure (HF).1 In the process of ventricular
remodeling, excess neurohormonal stimulation
increases left ventricular (LV) dimensions, myocar-
dial mass, and eventually, mortality rates.2 Several
large-scale clinical trials have clearly demon-
strated the benefits of β-adrenoceptor blockade
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Background/Purpose: Chinese are more sensitive to β-blockers than Caucasians. However, data regarding
β-blocker therapy in heart failure (HF) patients in Taiwan are lacking. We aimed to evaluate the improve-
ment of left ventricular function and the potential predictors of response to β-blocker therapy in Taiwanese
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Methods: We enrolled 34 HF patients with baseline left ventricular ejection fraction (LVEF) ≤ 40%. Beta-
blockers were titrated up to the maximum tolerable dose. LVEF prior to β-blocker usage and at the stable
dose were obtained. We also sequenced the entire gene encoding β1-adrenoceptor to assess the relation-
ships between LVEF improvement and gene polymorphisms.
Results: Beta-blocker therapy (25 ± 22 months) with a mean stable dose of 12 ± 8 mg carvedilol/day sig-
nificantly improved LVEF (from 28 ± 8% to 40 ± 15%, p < 0.001). Stepwise multiple linear regression
analysis identified dilated cardiomyopathy (bˆ = 18.32, p = 0.0004), baseline LVEF (bˆ = −0.85, p = 0.0020),
use of amiodarone (bˆ = −22.58, p = 0.0034) and square of digoxin dose (bˆ = −314.25, p = 0.0059) at stable 
β-blocker dose as independent predictors of LVEF improvement, where bˆ is the estimated regression coef-
ficient. We did not find any novel variant of β1-adrenoceptor gene other than those previously reported at
codons 49 and 389, with the allele distributions similar to those found in Caucasians, and these polymor-
phisms did not imply therapeutic response to β-blocker.
Conclusion: We demonstrated the therapeutic effects of β-blockers in Taiwanese HF patients with a dose
lower than what has been reported in Western people. Moreover, patients with the etiology of dilated car-
diomyopathy or lower baseline LVEF predicted a greater LVEF improvement. The β1-adrenoceptor gene
polymorphisms were not responsible for the difference in sensitivity to β-blockers in this Taiwanese 
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on morbidity and mortality in patients with symp-
tomatic HF or LV systolic dysfunction.3–6 The
beneficial effects may be associated with regres-
sion in myocardial mass, normalization of ven-
tricular geometry, improvement in LV ejection
fraction (LVEF), and antiarrhythmic property.7–9
Accordingly, β-blockers are recommended in con-
sensus guidelines for the management of systolic
HF.10,11
β-Blocker treatment should be initiated at a low
dose with careful titration to the highest tolerable
daily dose3,4,6 because there is a risk of cardiac
decompensation on the initiation of therapy in
certain patients. However, response to β-blockers
may vary among different ethnic groups. In healthy
subjects, Chinese are more sensitive to proprano-
lol with regard to the reduction in heart rate and
blood pressure than Caucasians.12 Beta-1 adreno-
ceptor (β1-AR) gene polymorphisms have been
reported to be associated with resting heart rate in
different ethnic groups of Americans.13 Two func-
tionally significant polymorphic loci at nucleo-
tides 145 (A to G) and 1165 (G to C) in the human
β1-AR gene have been identified, resulting in a
Ser49Gly and a Gly389Arg polymorphism respec-
tively.14–16 These two polymorphisms have also
been found to influence the response to β-blockers
in HF patients in Western countries.17–20
In this report, we aimed to assess the magni-
tude of LV function improvement, analyze the pre-
dictors responsible for the individual variation,
and to evaluate the impact of β1-AR gene poly-
morphisms on response to β-blocker therapy in
Taiwanese patients with HF.
Methods
Patients
A total of 34 consecutive patients with baseline
LVEF ≤ 40% and who were using one of the two
β-blockers carvedilol (n = 30) and metoprolol suc-
cinate (n = 4) were followed-up at the HF clinic
of National Taiwan University Hospital from
September 2005 to September 2006. Patients with
hypertrophic cardiomyopathy, hemodynamically
significant valvular lesions, bronchospastic lung
disease, baseline heart rate (HR) < 60/min or sys-
tolic blood pressure (BP) < 90 mmHg were not
enrolled. Patients who had coronary revascula-
rization within 3 months before the initiation of
β-blockers were also excluded. This study was 
approved by the institutional review board of
National Taiwan University Hospital and all 
enrolled patients gave written informed consent.
Study design
Beta-blockers were titrated up to the maximum
tolerable dose without a predefined time sched-
ule. The maximum tolerable dose was the daily
dose over which there was either (1) aggravation
of dyspnea or edema, (2) systolic BP < 90 mmHg
or HR < 60/min at rest, or (3) a need to increase
the concomitant medication for HF. At the time
prior to β-blocker usage and at the time of stable
β-blocker dose, defined as the maximal tolerable
dose which was unchanged for at least 3 months,
the following variables were collected: etiology
of HF, BP, HR, LVEF, concomitant medication,
and comorbidities. The dose of metoprolol was
expressed as an equivalent carvedilol daily dose
according to the proposed target daily doses in
clinical trials.3,4,6
Measurements of LVEF
LVEF was measured by echocardiography (n = 14)
or radionuclide left ventriculography (n = 20). 
At baseline and 3 months after stable dose of 
β-blockers, echocardiography was performed by
using 2.5- to 3.75-MHz transducers and the com-
mercially available system Sonos 5500 (Hewlett-
Packard Inc., Palo Alto, CA, USA). LVEF was
calculated from the biplane end-systolic and end-
diastolic volumes by computer software according
to area–length formula.21 LVEF based on radio-
nuclide left ventriculography was calculated as
described previously.22 For individual patients,
LVEF was evaluated by identical method at base-
line and at stable β-blocker dose. Persons who
analyzed the echocardiographic or radionuclide
angiographic parameters were blinded to the
treatment each patient received.
Polymerase chain reaction (PCR) and
sequence analyses
Genomic DNA was prepared from 1.5 mL of pe-
ripheral blood with a QIAamp DNA Blood Mini
Kit (Qiagen Inc., Valencia CA, USA) according to
the manufacturer’s protocol. A 2023-basepair seg-
ment, including the coding sequence, 482 nucleo-
tides in the 5-untranslated region (UTR) and
107 nucleotides in the 3-UTR of the β1-AR gene,
was amplified with forward (5 CTA GCT ACG
CGA TCA GCT CGG GAC T 3) and reverse (5
GAC GAG GAT TGT GGG CTT CGA GTT C 3)
primers. The reaction was processed in a 30-µL
mixture containing 200 ng genomic DNA, 0.2 µM
of each primer, 0.2 mM dNTPs, 1.5 mM MgCl2,
1.5 units GoTaq Flexi DNA polymerase (Promega
Corp., Madison, WI, USA), and 10% DMSO accor-
ding to the following condition: initial denatura-
tion at 94°C for 5 minutes, then 10 touch-down
cycles (94°C for 30 seconds, 65 to 55°C for 1
minute, and 72°C for 2 minutes), followed by 24
amplification cycles (94°C for 30 seconds, 58°C
for 1 minute, and 72°C for 2 minutes), and final
extension at 72°C for 5 minutes. The PCR product
was sequenced using a BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA, USA) and Applied Biosystems 3730
DNA Analyzers. The sites of polymorphisms were
confirmed by sequencing the opposite strand.
Statistical analysis
Statistical analyses were performed using SPSS
version 11.0 (SPSS Inc., Chicago, IL, USA) and SAS
version 8.0 (SAS Institute, Cary, NC, USA) statisti-
cal software. A p value ≤ 0.05 was considered stati-
stically significant. Continuous data are presented
as mean ± standard deviation, while categorical
data are presented as number (% of patients).
Comparisons between groups were made using
two-sample t test or Wilcoxon rank-sum test for
continuous variables and χ2 test or Fisher’s exact
test for categorical data. Simple linear regression
analysis was performed between the changes of
LVEF from baseline to stable dose (LVEF) and the
available covariates including patient characteris-
tics, β1-AR gene polymorphisms, and concomitant
medication at β-blocker stable dose. Stepwise mul-
tiple linear regression analysis was conducted using
the available covariates to identify the predictors
of LVEF with both significance level for entry
(SLE) and significance level for stay (SLS) set to
0.15. Coefficient of determination (R2) was com-
puted to evaluate the goodness-of-fit of the fitted
linear regression model. Statistical techniques for
regression diagnostics, including residual analysis,
detection of influential cases, and check for mul-
ticolinearity, were used to ensure the quality of
analysis results.
The estimate of each regression coefficient, bˆ,
is utilized to express the change in the mean of the
dependent variable (LVEF) for a unit change in
the independent variable (e.g. baseline LVEF), when
all other independent variables in the fitted multi-
ple linear regression model are held constant.
Results
Clinical characteristics
The demographic data for all enrolled patients
(n = 34) and different etiology groups are shown
in Table 1. There was no significant difference in
all baseline characteristics between patients with
coronary artery disease (CAD, n = 19) and dilated
cardiomyopathy (DCMP, n = 15) except for the
age and use of antiplatelet agents. The frequency
of methods employed for LVEF measurement was
not different between HF patients of CAD and
DCMP (Table 1, p = 0.563). Neither baseline LVEF
(27 ± 8% and 29 ± 8% respectively, p = 0.594) nor
LVEF (10 ± 15% and 14 ± 20% respectively, p =
0.354) was significantly different between patients
measured by radionuclide ventriculography and
those measured by echocardiography.
β-Blocker therapy (25±22 months) with a mean
stable dose of 12 ± 8 mg carvedilol/day improved
LVEF (p < 0.001) and reduced heart rate (p = 0.004)
without significant changes in blood pressure for
overall studied patients (Table 2). Subgroup analy-
ses based on the etiology of HF revealed that with
similar carvedilol doses and extent of heart rate
reduction between subgroups, the improvement
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in LVEF in patients with DCMP was more evi-
dent than that in CAD patients (p = 0.009).
Sequence analysis of the entire β1-AR gene re-
vealed no novel variants other than those previ-
ously reported at nucleotides 145 (A to G) and
1165 (G to C) within the coding region, with the
allele frequencies of 0.13 for Gly49 and 0.29 for
Gly389. There was no significant difference in al-
lele distributions between patients with CAD and
DCMP (p = 0.458 and 0.925 for codons 49 and
389, respectively).
Predictors of LVEF improvement
Simple linear regression analysis suggested that the
use of antiplatelet agents (bˆ = -11.54, p = 0.048),
baseline LVEF (bˆ = −1.05, p = 0.004), etiology of
DCMP (bˆ= 16.37, p = 0.004), and carvedilol stable
dose (bˆ = 0.78, p = 0.035) were positively (bˆ > 0)
or negatively (bˆ < 0) associated with the mean of
LVEF. Patient age was not correlated with the
magnitude of LVEF (p = 0.059). β1-AR gene poly-
morphisms had no significant association with
mean LVEF (bˆ=−4.23, p = 0.535 for Gly49 carrier;
bˆ = −0.99, p = 0.870 for Gly389 carrier).
In stepwise multiple linear regression analysis
of LVEF with the available covariates, etiology
of DCMP (bˆ = 18.32, p = 0.0004), baseline LVEF
(bˆ = −0.85, p = 0.0020), use of amiodarone (bˆ =
−22.58, p = 0.0034) and square of digoxin dose
(bˆ = −314.25, p = 0.0059) at β-blocker stable dose
H. Hu, et al
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Table 1. Patient characteristics*
Characteristics Overall (n = 34) CAD (n = 19) DCMP (n = 15) p†
Age, yr 58 ± 16 63 ± 13 52 ± 17 0.044
Male gender 25 (74) 16 (84) 9 (60) 0.139
BMI, kg/m2 25 ± 4 25 ± 4 26 ± 4 0.258
Duration of HF, mo 14 ± 24 22 ± 30 5 ± 7 0.096
LVEF, % 28 ± 8 30 ± 7 26 ± 8 0.130
Method for LVEF 0.563
RNA 20 (58.8) 12 (63.2) 8 (53.3)
UCG 14 (41.2) 7 (36.8) 7 (46.7)
Smoker 21 (62) 12 (63) 9 (60) 0.851
Alcohol use 6 (18) 3 (16) 3 (20) 1.000
Diabetes mellitus 10 (29) 6 (32) 4 (27) 1.000
Dyslipidemia 17 (50) 12 (63) 5 (33) 0.084
Hypertension 18 (53) 11 (58) 7 (47) 0.515
Atrial fibrillation 6 (18) 2 (11) 4 (27) 0.370
Medications Baseline Stable dose Baseline Stable dose Baseline Stable dose p† p‡
ACEI/ARB 28 (82) 27 (79) 15 (79) 15 (79) 13 (87) 12 (80) 0.672 1.000
Diuretics 28 (82) 28 (82) 15 (79) 14 (74) 13 (87) 14 (93) 0.672 0.196
Digoxin 13 (38) 11 (32) 8 (42) 7 (37) 5 (33) 4 (27) 0.601 0.715
Spironolactone 18 (53) 22 (65) 8 (42) 10 (53) 10 (67) 12 (80) 0.154 0.152
Nitrate 11 (32) 10 (29) 7 (37) 7 (37) 4 (27) 3 (20) 0.715 0.451
Antiplatelet agent 17 (50) 18 (53) 16 (84) 17 (90) 1 (7) 1 (7) < 0.001 < 0.001
Amiodarone 5 (15) 3 (9) 1 (5) 0 (0) 4 (27) 3 (20) 0.146 0.076
*Data are presented as mean ± standard deviation or n (%); p values for between-group (CAD vs. DCMP) comparisons †at baseline and ‡at stable dose.
CAD = coronary artery disease; DCMP = dilated cardiomyopathy; BMI = body mass index; HF = heart failure; LVEF = left ventricular ejection fraction; RNA =
radionuclide ventriculography; UCG = echocardiography; ACEI = angiotensin II converting enzyme inhibitor; ARB = angiotensin II receptor blocker.
independently predicted the mean of LVEF
(Table 3). This result indicated that, when other
covariates in the fitted multiple linear regression
model were held constant, mean LVEF in DCMP
patients was higher compared with that in CAD
patients at the magnitude of 18.32 units. It also
represented that mean LVEF decreased 0.85
units as the baseline LVEF increased 1 unit, and
so forth.
Two covariates with borderline significant p
values, patient age and the use of diuretics at β-
blocker stable dose, were also included in the final
fitted multiple linear regression model (Table 3)
under the consideration that the power of the
corresponding χ2 tests might not be large enough
due to the relatively small sample size (n = 34) of
this study. The coefficient of determination (R2)
was 0.6865, which is a goodness-of-fit measure of
the fitted multiple linear regression model. It in-
dicated that the correlation between the observed
value and the predicted value of the response
variable was about 0.83. The largest value of the
variance inflation factor (VIF) was 1.5378, indi-
cating no multicolinearity. However, the evidence
from our data was not strong enough to reject
the null hypothesis that β1-AR gene polymor-
phisms had no significant effect on mean LVEF
(bˆ = −1.432, p = 0.768 for Gly49 carrier; bˆ = 2.672,
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Table 2. Therapeutic response to carvedilol
Overall (n = 34) CAD (n = 19) DCMP (n = 15)
p§
Baseline Stable dose p‡ Baseline Stable dose p‡ Baseline Stable dose p‡
Carvedilol*, mg – 12 ± 8 – – 10 ± 6 – – 14 ± 10 – 0.312||
Heart rate, 83 ± 15 77 ± 11 0.004 80 ± 13 73 ± 9 0.011 88 ± 16 80 ± 12 0.087 0.715
beats/min
Blood pressure, 
mmHg
Systolic 125 ± 20 124 ± 17 0.984 127 ± 20 125 ± 19 0.981 120 ± 22 122 ± 14 0.726 0.927
Diastolic 75 ± 13 71 ± 11 0.096 75 ± 13 71 ± 13 0.162 73 ± 15 72 ± 9 0.529 0.841
LVEF, % 28 ± 8 40 ± 15 < 0.001 30 ± 7 34 ± 10 0.077 26 ± 8 47 ± 18 0.001 0.009
ACEI/ARB†, % 28 ± 24 36 ± 34 0.181 28 ± 25 34 ± 33 0.442 28 ± 24 38 ± 37 0.258 0.797
Digoxin, mg 0.06 ± 0.09 0.04 ± 0.08 0.109 0.06 ± 0.09 0.04 ± 0.07 0.093 0.06 ± 0.10 0.05 ± 0.10 0.705 0.291
*Stable daily dose of carvedilol; †percentage of the recommended daily dose for ACEI/ARB; ‡p value for within-group comparisons (baseline vs. stable
dose); §p value for between-group (CAD vs. DCMP) comparisons of change from baseline values; ||comparison of b-blocker stable dose between CAD and
DCMP groups. CAD = coronary artery disease; DCMP = dilated cardiomyopathy; LVEF = left ventricular ejection fraction; ACEI = angiotensin II converting
enzyme inhibitor; ARB = angiotensin II receptor blocker.
Table 3. Multiple linear regression analysis of left ventricular ejection fraction (LVEF) improvement 
(LVEF, %) (n = 34)*
Covariate Estimate of regression coefficient (bˆ) Standard error Wald χ2 test p
Intercept 53.5644 12.5104 4.28 0.0002
Age −0.2380 0.1301 −1.83 0.0784
Etiology of DCMP 18.3238 4.5504 4.03 0.0004
Baseline LVEF (%) −0.8526 0.2487 −3.43 0.0020
Use of diuretics† −9.4017 5.0561 −1.86 0.0739
Use of amiodarone† −22.5806 7.0394 −3.21 0.0034
Square of digoxin dose† −314.2464 105.0397 −2.99 0.0059
*Coefficient of determination (R2) = 0.6865, the largest value of variance inflation factor = 1.5378; †at b-blocker stable dose. DCMP =
dilated cardiomyopathy.
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p = 0.525 for Gly389 carrier) after adjusting for the
effects of other covariates.
Discussion
In this study, we demonstrated that in Taiwanese
patients with HF, β-blockers produced significant
improvement in LVEF at a stable daily dose as
low as 12 ± 8 mg of carvedilol. In the MOCHA
trial, carvedilol (12.5–50 mg/day) generated dose-
related LVEF improvement (5–8%) in HF patients,
of whom 77% were Caucasians.8 The mean car-
vedilol dose in our patients was even less than the
minimum dose used in the MOCHA trial, but the
magnitude of the LVEF improvement in our study
was higher than that in all of their dosing groups.
In Japanese patients with HF, carvedilol at a dose
as low as 5 mg/day reduced cardiovascular-related
death or hospitalization, and a dose of 20 mg/day
could further improve LVEF (13%).23 A recent
study indicated that in Japanese DCMP patients on
a carvedilol maintenance dose of 14 mg/day for
6 months, LVEF significantly increased from 28%
to 39%.24 In concordance with the studies on
Japanese, our result implied that β-blockers might
provide substantial therapeutic effects in Asian
populations at a dose lower than that applied to
Western people.
Since the polymorphisms at nucleotides 145
(A to G) and 1165 (G to C) in the human β1-AR
gene were found to correlate with improvement
in patient survival or with the reverse of LV re-
modeling after β-blockade therapy,17–20 it was
speculated that β1-AR gene polymorphisms might
have a significant impact on Taiwanese patients
with HF. However, we did not find any statisti-
cally significant associations between the poly-
morphisms at codons 49 or 389 and LVEF after
adjusting for the effects of the other covariates
(Table 3). Furthermore, there was neither novel
variant within the coding region of the β1-AR
gene nor difference in the allele distribution be-
tween our patients and Caucasians with HF.14,15
Thus, the difference in therapeutic response to 
β-blockers between Taiwanese and Caucasians
could not be explained by the β1-AR gene 
polymorphisms.
In this report, patients who had lower LVEF at
baseline achieved greater improvement in LVEF
after β-blocker therapy. This may be explained by
the fact that patients with a greater magnitude of
sympathetic activation secondary to suppressed LV
contractility would get more beneficial responses
from β-blocker therapy.1 We also found that pa-
tients with DCMP had a greater improvement in
LVEF than those with CAD. Myocardial oxygen
demands may be increased as a result of the in-
creased wall tension in patients with non-ischemic
cardiomyopathy.25 The global subendocardial is-
chemia might form a homogeneous substrate for
β-blocker action.26 In contrast, the heart of the pa-
tient with ischemic cardiomyopathy is comprised
of a larger quantity of nonviable myocardium that
is not amenable to β-blocker treatment.27 Thus, the
regression analysis of our study as well as previous
studies identified non-ischemic cardiomyopathy
as an independent predictor of LVEF improvement
in β-blockade therapy.28,29
The significant difference in age between pa-
tients with DCMP and CAD in this report might
be due to the difference in preferential onset age
of these two disease categories. The exclusion of
patients who had recently undergone revascular-
ization (n = 5; age, 57±10 years) might further 
exaggerate the advanced age in our CAD popula-
tion. Thus, the etiology of DCMP, instead of pa-
tient age, was an independent predictor of LVEF
in the stepwise multiple regression analysis. Our
result is supported by the findings of a large-scale
clinical trial that indicated that age is not a deter-
minant for the efficacy of β-blockade therapy in
patients with HF.30
Although two different methods were used to
measure LVEF, individual patients were evaluated
by using identical method at baseline and at sta-
ble β-blocker dose. Besides, neither baseline LVEF
nor LVEF was significantly different between
patients measured by radionuclide ventriculog-
raphy and those measured by echocardiography.
Thus, we might preclude the potential impact of
different measurement methods of LVEF.
The squared digoxin dose as a negative signifi-
cant predictor indicated that there was a nonlinear
relationship between digoxin dose and mean
LVEF (Table 3). High dose digoxin may increase
myocardial necrosis and mortality in mice with
viral myocarditis.31 Although low dose digoxin
may prevent patients from deterioration of HF,32
high serum digoxin concentrations were associ-
ated with increased mortality.33 Thus, it might be
worthwhile to cautiously titrate the digoxin dose
in the treatment of HF patients.
Only three patients in this study received amio-
darone at β-blocker stable dose, and all of them
had the indication of ventricular arrhythmia. Two
of them eventually passed away, and the remaining
one underwent defibrillator implantation. There-
fore, the negative predictive effect of amiodarone
use might actually reflect the poor prognosis of
ventricular arrhythmia in HF patients.
Several limitations of this small-size open-
labeled study should be considered. First, in the
absence of a placebo-control group, changes in
LV function might be confounded by disease pro-
gress or by concomitant medication. Second, com-
pared with the short dosing interval and forced
dose escalation in previous reports, our titration
intervals for β-blocker dosages were individual-
ized and were much longer. In addition, with the
differences in β-adrenoceptor selectivity and phar-
macokinetic properties between carvedilol and
metoprolol, some bias might be introduced by
the arbitrary dose conversion.34 Furthermore, the
effects of β1-AR gene polymorphisms on the sen-
sitivity to β-blocker might be obscured due to our
limited sample size. Future double blind, placebo-
controlled studies with larger sample size are
needed to confirm the findings in this report.
In conclusion, we demonstrated the significant
improvement in LVEF in response to low-dose 
β-blockade therapy in Taiwanese patients with HF.
Moreover, dilated cardiomyopathy as the etiology
of HF and lower baseline LVEF predicted a greater
improvement in LVEF. We did not find any novel
variant within the coding region of the β1-AR
gene or a different allele distribution pattern of
codons 49 and 389. Based on the results of this
study, β1-AR gene polymorphisms are not respon-
sible for the difference in sensitivity to β-blockers
in this Taiwanese population with HF.
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